Clinical Trials Browser

RG7388 × Clear all

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1/2 Terminated

38 enrolled 34 charts

CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Completed

33 enrolled 26 charts

Chromosome 17 deletion, Multiple Myeloma

NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Phase 1 Withdrawn

Central Nervous System Neoplasms, Rhabdoid Tumor

NCT03555149 2023-11-07

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Phase 1/2 Terminated

96 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

Glioblastoma

NCT02545283 2022-01-11

MIRROS

Phase 3 Terminated

447 enrolled 24 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02670044 2022-01-03

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03287245 2021-12-08

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Phase 2 Terminated

27 enrolled 28 charts

Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Terminated

29 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03566485 2021-08-11

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Breast Neoplasms

NCT02624986 2020-05-18

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Phase 1/2 Terminated

25 enrolled 21 charts

Lymphoma, Non-Hodgkin

NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Phase 1 Completed

Polycythemia Vera, Thrombocythemia, Essential

NCT03362723 2019-06-19

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumors